Abstract 404P
Background
Birociclib is a selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. This phase II study (NCT04539496) was to evaluate the efficacy and safety of birociclib as single-agent in patients with refractory HR+/HER2- metastatic breast cancer (MBC).
Methods
The patients with HR+/HER2- MBC who had progressed after prior endocrine therapy and 1-2 prior chemotherapy regimens in the metastatic setting were eligible. Birociclib 480 mg was administered orally on a continuous schedule twice daily until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) assessed by Independent Reivew Committee (IRC) per RECIST v1.1. Other endpoints included investigator-assessed ORR,duration of response (DoR), progression-free survival (PFS), overall survival (OS) and safety,etc.
Results
131 patients were enrolled from 29 hospitals in China between 10/2020 and 08/2021. As of Nov 30, 2022, the median duration of follow-up was 19.0 months. Median duration of treatment was 6 months. The majority (84.7%) patients had visceral metastasis, 60.3% of patients had ≥3 metastatic organs. In the metastatic setting, patients had received a median of 3 prior systemic therapies including a median of 1 chemotherapy regimen and 2 endocrine therapy regimens. The main results are shown in the table. Table: 404P
Responses according to RECIST v1.1
| BOR n(%) | IRC-assessed N=131 | Investigator-assessed N=131 |
| CR | 0 | 1 (0.8) |
| PR | 38 (29.0) | 29 (22.1) |
| ORR (%)[95% CI] | 29.0 [21.4, 37.6] | 22.9 [16.0, 31.1] |
| DCR (%)[95% CI] | 73.3 [64.8, 80.6] | 66.4 [57.6, 74.4] |
| CBR (%)[95% CI] | 42.0 [33.4, 50.9] | 39.7 [31.3, 48.6] |
| mDoR (m) [95% CI] | 14.8 [9.5, 16.7] | 13.1 [9.4, 14.8] |
| mPFS (m) [95% CI] | 11.0 [7.3,12.9] | 8.3 [5.5, 9.3] |
| mOS (m) [95% CI] | 24.3 [24.3, -] | |
| 24m OS rate | 62.9% |
The most common treatment-emergent adverse events (TEAEs) were gastrointestinal and hematological toxicity, common to CDK4/6 inhibitors. Most of these AEs were grade 1-2, and manageable with supportive treatments.
Conclusions
In patients with refractory HR+/HER2- MBC who have previously received chemotherapy and endocrine therapy, continuous dosing of single-agent birociclib exhibited promising and sustaining clinical activity with manageable toxicities, thus it provides an alternative orally single-agent therapy.
Clinical trial identification
NCT04539496.
Editorial acknowledgement
Legal entity responsible for the study
Xuanzhu Biopharmaceutical Co., Ltd.
Funding
Xuanzhu Biopharmaceutical Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
392P - The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer on first-line endocrine therapy with or without a CDK 4/6 inhibitor
Presenter: Senna Lammers
Session: Poster session 03
393P - Real-world (RW) use patterns, effectiveness, and tolerability of sacituzumab govitecan (SG) for second-line (2L) and later treatment of metastatic triple-negative breast cancer (mTNBC)
Presenter: Kevin Kalinsky
Session: Poster session 03
394P - CDK4/6 inhibitors in metastatic breast cancer: An Italian real-world experience
Presenter: Francesco Pantano
Session: Poster session 03
395P - Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Presenter: Kyung Jung
Session: Poster session 03
396P - Real-world treatment and survival outcomes in previously untreated patients with metastatic triple-negative breast cancer (mTNBC) in the United States (US)
Presenter: Kevin Punie
Session: Poster session 03
398P - A phase Ib/II study of IN10018/FAKi in combination with pegylated liposomal doxorubicin (PLD) and toripalimab in metastatic triple-negative breast cancer (TNBC): IN10018-010
Presenter: Xichun Hu
Session: Poster session 03
399P - Results from a first-in-human phase Ia/b study of LX-039, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal patients with ER+, HER2- advanced breast cancer (ABC)
Presenter: weina shen
Session: Poster session 03
400P - The impact of CDK4/6 inhibitors on bone health: An Italian real-world experience
Presenter: Roberta Scafetta
Session: Poster session 03
401P - Utidelone in combination with etoposide and bevacizumab in HER2-negative breast cancer with brain metastasis (UTOBIA-BM): A prospective, single-arm, phase II trial
Presenter: Yehui Shi
Session: Poster session 03